Want to see AU:AVE full AI Analyst Report?
Top Page
Avecho Biotechnology Limited
(Sydney:AVE)
Select Model
Select Model
Rating:54Neutral
Price Target:
AU$0.02
â–²(140.00% Upside)
Action:Reiterated
Date:07/01/26
The score is driven primarily by mixed financial performance: improving revenue and a 2025 cash-flow turnaround with low leverage, but persistent net losses and declining equity remain significant risks. Technicals are supportive with the price well above short-term moving averages, while valuation is constrained by a negative P/E and no indicated dividend yield.
Positive Factors
Proprietary TPM drug‑delivery platform
Avecho’s proprietary Tocopheryl Phosphate Mixture (TPM) is a durable technological asset that supports formulation advantages across pharmaceuticals and nutraceuticals. A platform model enables licensing, recurring royalties and partner development, fostering scalable, margin‑enhancing revenue streams over time.
Negative Factors
Persistent operating and net losses
Despite revenue gains, recurring operating and net losses materially erode profitability and require ongoing capital or partner funding. Persistent negative earnings constrain the ability to build retained earnings, limit reinvestment capacity and raise long‑term sustainability concerns if losses persist.
Read all positive and negative factors
Positive Factors
Negative Factors
Proprietary TPM drug‑delivery platform
Avecho’s proprietary Tocopheryl Phosphate Mixture (TPM) is a durable technological asset that supports formulation advantages across pharmaceuticals and nutraceuticals. A platform model enables licensing, recurring royalties and partner development, fostering scalable, margin‑enhancing revenue streams over time.
Read all positive factors
Avecho Biotechnology Limited (AVE) vs. iShares MSCI Australia ETF (EWA)
Market Cap
AU$81.14M
Dividend YieldN/A
Average Volume (3M)N/A
Price to Earnings (P/E)―
Beta (1Y)1.28
Revenue Growth9.28%
EPS Growth-40.00%
CountryAU
Employees9
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding3,863,725,800
10 Day Avg. VolumeN/A
30 Day Avg. VolumeN/A
Financial Highlights & Ratios
PEG Ratio-0.16
Price to Book (P/B)18.85
Price to Sales (P/S)23.75
P/FCF Ratio26.65
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Avecho Biotechnology Limited Business Overview & Revenue Model
Company Description
Avecho Biotechnology Limited, a biotechnology company, develops and commercializes human and animal health products using its proprietary drug delivery system, tocopherol phosphate mixture (TPM) in Australia, Switzerland, France, and India. It ope...
How the Company Makes Money
Avecho’s monetisation model is primarily based on commercialising its proprietary TPM drug-delivery technology and any products formulated using it. Revenue can be generated through (1) licensing TPM to partners for use in their products, which ty...
Avecho Biotechnology Limited Financial Statement Overview
Summary
Income Statement
28
Negative
Balance Sheet
52
Neutral
Cash Flow
57
Neutral
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 1.24M | 1.13M | 473.55K | 1.13M | 793.60K |
| Gross Profit | 751.29K | 671.93K | -43.80K | 793.12K | 507.94K |
| EBITDA | -5.87M | -2.92M | -3.24M | -2.11M | -2.98M |
| Net Income | -4.42M | -3.12M | -3.44M | -2.34M | -3.42M |
Balance Sheet | |||||
| Total Assets | 7.11M | 5.00M | 7.32M | 3.35M | 5.25M |
| Cash, Cash Equivalents and Short-Term Investments | 4.66M | 2.37M | 5.50M | 1.47M | 3.26M |
| Total Debt | 14.47K | 1.08M | 175.15K | 246.07K | 93.91K |
| Total Liabilities | 5.55M | 1.73M | 941.54K | 920.66K | 709.36K |
| Stockholders Equity | 1.56M | 3.27M | 6.38M | 2.42M | 4.54M |
Cash Flow | |||||
| Free Cash Flow | 1.10M | -3.97M | -3.18M | -1.72M | -3.30M |
| Operating Cash Flow | 1.10M | -3.97M | -3.18M | -1.67M | -3.10M |
| Investing Cash Flow | 0.00 | -15.73K | 0.00 | -53.12K | -202.82K |
| Financing Cash Flow | 1.19M | 854.59K | 7.22M | -78.22K | 4.69M |
Avecho Biotechnology Limited Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
55 Neutral | AU$76.76M | -7.13 | -62.49% | ― | ― | -13.64% | |
54 Neutral | AU$81.14M | -15.71 | -258.19% | ― | 9.28% | -40.00% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
43 Neutral | AU$102.35M | -1.96 | -265.55% | ― | -26.58% | -100.90% | |
41 Neutral | AU$46.52M | -0.41 | -134.65% | ― | ― | 62.72% | |
41 Neutral | AU$115.30M | -3.45 | 279.21% | ― | ― | -37.23% | |
40 Underperform | AU$79.58M | -0.92 | -69.20% | ― | ― | -73.11% |
* Healthcare Sector Average
AU:AVE
Avecho Biotechnology Limited
0.02
0.01
110.00%
AU:IMU
Imugene
0.10
-0.28
-74.32%
AU:PAR
Paradigm Biopharmaceuticals
0.18
-0.24
-57.32%
AU:IMM
Immutep Ltd
0.05
-0.21
-79.23%
AU:PTX
Prescient Therapeutics Limited
0.07
0.03
55.32%
AU:RCE
Recce Pharmaceuticals Ltd.
0.39
0.04
10.00%
Avecho Biotechnology Limited Corporate Events
Avecho Biotechnology Seeks ASX Quotation for 33 Million New Shares
Jun 30, 2026
Avecho Biotechnology Limited has applied for ASX quotation of new ordinary fully paid shares following the conversion of options or other convertible securities. The application covers the listing of a total of 33,277,616 additional shares issued ...
Avecho to Brief Investors on Interim Results of Pivotal CBD Insomnia Trial
Jun 22, 2026
Avecho Biotechnology, a Melbourne-based biotech specialising in TPM-enhanced human and animal health products, is advancing a proprietary CBD TPM soft-gel capsule as its lead asset for insomnia. The technology aims to improve drug absorption and i...
Avecho Seeks Trading Halt Ahead of Key Phase III CBD Insomnia Trial Update
Jun 21, 2026
Avecho Biotechnology has requested an immediate trading halt for its ordinary shares on the Australian Securities Exchange, in line with ASX Listing Rule 17.1, as it prepares to release the outcome of an interim analysis of its Phase III trial for...
Avecho Issues 7.9 Million Unquoted Options Under Employee Incentive Scheme
Jun 2, 2026
Avecho Biotechnology has notified the market of the issue of 7,923,243 unquoted options under its employee incentive scheme, with various exercise prices and expiry dates, effective 1 June 2026. The move expands the company’s pool of employe...
Avecho director Matthew McNamara steps down, updates shareholdings
May 31, 2026
Avecho Biotechnology Limited has announced that director Matthew Patrick McNamara ceased to be a director of the company on 25 May 2026. The change in board composition is disclosed through a final director’s interest notice, in line with AS...
Avecho launches no-cost facility to sell small shareholdings
May 27, 2026
Avecho Biotechnology Limited has launched a small holding share sale facility for investors whose Avecho share parcels are valued at less than $500, based on a record date price of $0.012. The initiative covers 33,843,652 shares held by 2,934 shar...
Avecho secures strong shareholder backing at 2026 AGM as all put resolutions pass
May 26, 2026
Avecho Biotechnology reported the voting outcomes of its 2026 Annual General Meeting, confirming that all resolutions put to shareholders, including the adoption of the remuneration report and ratifications of prior share and option issues, were c...
Avecho strengthens balance sheet as Phase III insomnia trial nears key read-out
May 26, 2026
Avecho Biotechnology used its 2026 AGM to highlight steady execution of its strategy following the licensing of Australian commercial rights for its TPM‑enhanced cannabidiol soft-gel capsule to Sandoz. The company reported a markedly stronge...
Avecho Director Resigns as CBD Insomnia Program Enters Critical Phase
May 25, 2026
Avecho Biotechnology has announced the resignation of non-executive director Matthew McNamara, effective 25 May 2026, after nearly seven years on the board, prompting the withdrawal of his re-election resolution from the upcoming AGM but leaving t...
Avecho readies Phase III interim analysis on CBD insomnia capsule amid surging sleep market
May 25, 2026
Avecho Biotechnology is advancing its TPM-based drug delivery platform, focusing on human and animal health applications that enhance oral, dermal and transdermal absorption, with its main product a cannabidiol soft-gel capsule aimed at improving ...
Avecho Secures A$1.98m R&D Tax Refund to Advance CBD Insomnia Program
May 22, 2026
Avecho Biotechnology has received A$1.98 million under the Australian Government’s RD Tax Incentive Scheme for the year ended 31 December 2025, underscoring its ongoing investment in differentiated cannabinoid formulations aimed at pharmaceu...
Avecho hits key milestone in Phase III CBD insomnia trial ahead of interim data
May 21, 2026
Avecho Biotechnology has completed the treatment phase for the 244 patients needed for an interim analysis of its pivotal Phase III trial of a TPM-enhanced cannabidiol capsule for insomnia. The study, designed to support Australian regulatory regi...
Avecho director reshapes indirect stake as options exercised and lapse
May 13, 2026
Avecho Biotechnology has reported a change in the indirect holdings of director Gregory Collier, primarily through his interests in Beacon Super Fund Pty Ltd and Barwon Biotechnology Pty Ltd. The disclosure details the restructuring of his exposur...
Avecho seeks ASX quotation for nearly 150m new shares
May 13, 2026
Avecho Biotechnology Limited has applied to the ASX for quotation of 149,983,861 new ordinary fully paid shares following recent security issuances. The application covers two tranches, with 3,316,013 shares issued on 8 May 2026 and 146,667,848 sh...
Avecho lifts cash and streamlines capital ahead of pivotal CBD insomnia trial milestone
May 12, 2026
Avecho Biotechnology has boosted its balance sheet with approximately $1.9 million from the exercise of listed AVEOA options before their expiry, taking pro forma cash to about $6.3 million as at 31 March 2026 and lifting shares on issue to 3.83 b...
Avecho Seeks ASX Quotation for Newly Issued Shares
May 7, 2026
Avecho Biotechnology Limited has applied to the ASX for quotation of new ordinary fully paid shares following the issue of additional securities. The company will have 1,807,146 new shares quoted from 4 May 2026 and a further 5,193,571 shares quot...
Avecho appoints new company secretary to strengthen ASX governance
May 1, 2026
Avecho Biotechnology has appointed experienced corporate lawyer and company secretary Naomi Lawrie as its new Company Secretary, effective 1 May 2026, following internal team changes at its corporate services provider Vistra Australia. Lawrie, who...
Avecho Flags Imminent Option Expiry as It Advances CBD Insomnia Trial
Apr 29, 2026
Avecho Biotechnology has notified holders of its listed options (ASX: AVEOA) that the options, exercisable at $0.012, will expire at 5:00pm AEST on 10 May 2026, with trading to cease on 4 May 2026. Option holders may choose to exercise all or part...
Avecho Exceeds Phase III Insomnia Trial Target as Key Interim Read-Out Nears
Apr 28, 2026
Avecho Biotechnology has surpassed its recruitment target for the interim analysis of its pivotal Phase III trial of a TPM-enhanced CBD soft-gel capsule for insomnia, randomising 244 patients, 16% above plan, to strengthen statistical power. The m...
Avecho sets 2026 AGM date and shifts to digital meeting materials
Apr 23, 2026
Avecho Biotechnology Limited has scheduled its Annual General Meeting for Tuesday, 26 May 2026 at 1:00pm AEST, to be held at Grant Thornton’s offices in Collins Square, Melbourne. Shareholders are encouraged to participate either in person o...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.